Related Experiment Video
Updated: Jun 2, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Amyloidosis: pathogenesis and new therapeutic options
Giampaolo Merlini1, David C Seldin, Morie A Gertz
1Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, P. le Golgi, 19, 27100 Pavia, Italy. gmerlini@smatteo.pv.it
Summary
Early diagnosis and individualized treatment are crucial for managing immunoglobulin light chain amyloidosis (AL), a complex disease involving protein deposition and organ damage. Treatment strategies are guided by patient factors and cardiac involvement.
Area of Science:
- Hematology
- Oncology
- Cardiology
Background:
- Systemic amyloidoses involve misfolded protein deposition, leading to progressive organ damage.
- Immunoglobulin light chain amyloidosis (AL) is the most common type, stemming from abnormal plasma cells producing misfolded light chains.
Purpose of the Study:
- To offer current insights into the diagnostic and therapeutic strategies for AL amyloidosis.
- To emphasize the importance of early and precise diagnosis for effective treatment.
Main Methods:
- Review of current literature and clinical practices in AL amyloidosis.
- Discussion of diagnostic technologies, cardiac staging, and treatment modalities.
Main Results:
- Accurate diagnosis, potentially requiring advanced techniques, is paramount for successful therapy.
- Cardiac involvement significantly influences prognosis and treatment selection.
- Individualized treatment plans consider patient age, organ function, and potential toxicities, guided by biomarkers.
Conclusions:
- Alkylator-based chemotherapy is effective in a majority of AL amyloidosis patients.
- Novel agents show promise, with ongoing trials to optimize their use.
- Future treatment algorithms will incorporate new drug targets and therapeutic approaches identified through research.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...